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Abstract 
Kallikrein-related peptidases KLK5, KLK7 and KLK14 are important proteases in skin 
desquamation and aberrant KLK activity is associated with inflammatory skin diseases such 
as Netherton syndrome but also with various serious forms of cancer. Previously, we have 
identified KLK7 as the first protease target of vaspin (Serpin A12). Here, we report KLK14 as 
a second KLK protease to be inhibited by vaspin. In conclusion, vaspin represents a multi-
specific serpin targeting the kallikrein proteases KLK7 and KLK14, with distinct exosites 
regulating recognition of these target proteases and opposing effects of heparin binding on the 
inhibition reaction. 
Keywords: adipokine, exosite, kallikrein, obesity, diabetes, metabolic syndrome, 
inflammation, serine protease, serpin A12, site‐directed mutagenesis, structural 
biology 
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Visceral adipose tissue-derived serpin (vaspin) is a member of the serine protease inhibitor 
family (Serpin A12) and exhibits various beneficial effects on obesity-related diseases 
(Heiker, 2014). Inhibitory serpins form covalent complexes with serine proteases under 
incorporation of the reactive center loop (RCL) into their central β-sheet A (Stratikos and 
Gettins, 1999). Vaspin does not inhibit common serine proteases such as trypsin, elastase, 
urokinase, factor Xa, collagenase and dipeptidyl peptidase (Hida et al., 2005). Kallikrein 7 
(KLK7), a protease with chymotrypsin-like specificity (Egelrud and Lundstrom, 1991), was 
identified as the first vaspin target protease (Heiker et al., 2013). Vaspin did not inhibit the 
closely related kallikrein proteases KLK4 and KLK5 (Heiker et al., 2013), which are both 
proteases with trypsin-like specificity (Debela et al., 2006). KLK7 is the most abundantly 
expressed KLK in the stratum corneum (Komatsu et al., 2006) and, with contributions of 
KLK5 and KLK14, the major enzyme involved in corneocyte shedding (de Veer et al., 2017). 
Aberrant activities of these KLKs are related to inflammatory skin diseases such as Netherton 
syndrome (Kasparek et al., 2017), psoriasis (Ekholm and Egelrud, 1999) and acne rosacea 
(Yamasaki et al., 2007). KLK7 and vaspin have been shown to be co-expressed in human skin 
(Schultz et al., 2013) as well as in pancreatic islets (Heiker et al., 2013). KLK14 is a member 
of the kallikrein family that displays both trypsin- and chymotrypsin-like activity (Felber 
et al., 2005) and was tested here as a potential target protease of vaspin. 
Figure 1 demonstrates the inhibitory activity of different vaspin variants against the known 
protease target KLK7 and the newly identified target KLK14. As previously shown, vaspin 
wildtype (wt) forms stable serpin-protease complexes with KLK7 (Figure 1A) with an 
apparent molecular weight of ~70 kDa. In comparison, complex formation of vaspin with 
KLK14 was also observed (Figure 1B), though complex formation is much slower. Additional 
bands at a molecular weight of ~44 kDa and ~42 kDa represent fragments derived by 
proteolytic cleavage of the N-terminus and of the reactive center loop (RCL) of vaspin, 
respectively. For KLK7, N-terminal processing after Y30 of vaspin results in release of a short 
decapeptide vaspin(L20-Y30) (Ulbricht et al., 2017). Also with KLK14 we observed specific 
N-terminal cleavage of vaspin, but after R28 (Supplementary Figure 1, Supplementary 
Table 1), which is in agreement with the strong trypsin-like arginine preference of KLK14 at 
the P1 position (Felber et al., 2005). It is unknown, whether these peptides inherit any 
biological function, as e.g. described for a peptide derived from the N-terminal sequence of 
PEDF (Serpin F1) (Koskimaki et al., 2012). The N-terminally truncated vaspin retains full 
inhibitory activity (Ulbricht et al., 2017). Incubation of vaspin with KLK14 yielded an 
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additional protein band with an apparent molecular weight of ~35 kDa (Figure 1B, 180 min). 
Tryptic in-gel digestion of the protein band and subsequent mass spectrometry (MS) 
identified multiple vaspin-derived peptides covering the middle of the molecule (residues 
130 – 280; data not shown). By using a substrate variant of vaspin bearing the A369P 
mutation, we could demonstrate that this vaspin fragment results from KLK14 cleavage of 
native or cleaved vaspin but not from specific degradation of the serpin-protease complex 
(Figure 1C). As previously shown, the A369P mutation retards RCL integration into the 
central β-sheet A and enables the protease to escape the serpin-mechanism by facilitating 
RCL cleavage (Pippel et al., 2016). 
Chymotrypsin-like KLK7 cleavage in the vaspin RCL has been shown to occur after M378 
(Heiker et al., 2013), which is in line with reported subsite preferences of KLK7 (Debela 
et al., 2006). MS analysis of KLK14-cleaved vaspin revealed the same scissile bond within 
the RCL sequence as targeted by KLK7 (Supplementary Figure 1, Supplementary Table 1), 
which is in agreement with previously reported cleavage of the antitrypsin RCL for KLK14 
(Felber et al., 2006).  
Thus, both proteases attack the same peptide bond between P1 residue M378 and P1’ residue 
E379. For KLK7, we have demonstrated the repressing effect of E379 on vaspin activity, as the 
P1’ site mutation of glutamate to serine (E379S) resulted in substantial acceleration of KLK7 
inhibition (Ulbricht et al., 2015). A scissile bond of P1 Met – P1’ Ser resembles the cleavage 
site in antitrypsin (Serpin A1), a very good inhibitor of KLK7 and KLK14 (Felber et al., 
2006; Luo and Jiang, 2006). Mutation of the P1 site to a more preferred Tyr (M378Y) only 
resulted in minor improvement of KLK7 inhibition (Pippel et al., 2016), demonstrating the 
P1’ site as the decisive regulatory element of inhibition rate within the RCL.  
KLK7 is unable to cleave the synthetic RCL-derived peptide comprising vaspin residues T365-
K388 and thus exosite interactions are essential for the efficient inhibition of KLK7 by vaspin 
(Ulbricht et al., 2015). To investigate whether exosites are equally important for vaspin 
activity towards KLK14, the same vaspin RCL-derived peptide was incubated with KLK14. 
As also observed for KLK7, this peptide was not cleaved by KLK14 (Supplementary Figure 
2) indicating that the P1’ residue E379 is also a negative regulatory element for KLK14. This 
was supported by complex formation analysis using the E379S vaspin mutant (Figure 1D). 
Exchange of P1’ Glu did clearly accelerate the inhibition reaction, though not in the same 
extent as it does affect the KLK7 inhibition reaction (Figure 1D). Together, these data suggest 
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the P1’ glutamate as the primary determinant of specificity for vaspin. Furthermore, these 
results indicate the requirement of exosite interactions for efficient inhibition of KLK14 by 
vaspin.  
Vaspin residue R302, located in the β-sheet C and close to the RCL cleavage site, was 
identified as the crucial exosite for KLK7 recognition and inhibition (Ulbricht et al., 2015). 
Complex formation is much slower and the inhibition rate is significantly decreased for 
vaspin mutants lacking R302 (Figure 1A and Table 1). 
For the inhibition of KLK14, striking differences for the vaspin wt and variants were 
observed. First and as mentioned before, inhibition of KLK14 by vaspin wt is a significantly 
slower than inhibition of KLK7, with inhibition rates of 1.0 mM1 s1 compared to 12.3 mM1 s1 
(Table 1). Furthermore, while mutation of the exosite residue R302 (R302A) dramatically 
decreased the inhibition rate for KLK7 (down to 0.3 mM-1 s-1, Table 1), kinetic analysis 
revealed a small increase in KLK14 inhibition rate for R302A compared to the wt (1.5 mM-1 
s-1). These data imply that R302 is not an essential exosite for KLK14 recognition. Instead, the 
arginine side chain in the wt seems to slightly hinder serpin protease interaction, affecting 
both the inhibitory and substrate pathway (Figure 1B). 
Previously, an artificial disulfide mutant of vaspin (D305C/V383C) showed a 5-fold increase 
in inhibitory activity towards KLK7 (Ulbricht et al., 2015). We generated the vaspin mutant 
D305A to investigate this aspartate residue as a potential second exosite regulating or fine-
tuning protease specificity. Indeed, the D305A mutant exhibited a significantly accelerated 
inhibition rate for KLK7 (89.7 mM-1 s-1, Table 1), suggesting a repulsive effect of the 
negatively charged side chain on KLK7. The stoichiometry of inhibition (SI) for KLK7 and 
vaspin D305A was also decreased, indicating a more efficient inhibition reaction compared to 
the wt (1.8 vs 3.6, Table 1). In contrast, the mutation of D305 to alanine did not affect KLK14 
inhibition and kinetic parameters were similar to the vaspin wt (Figure 1B, Table 1). 
Densitometric estimation of the SI from SDS-gels also gave comparable values for vaspin wt 
and variants (Table 1). Notably, serpin-protease complexes of both mutants, R302A and 
D305A, were stable for at least 24 h, but KLK14 complexes with vaspin wt were only stable 
up to 7 h (data not shown) and were not detected after prolonged incubation (Figure 1E). 
Serpin-enzyme complexes are cleared from the circulation rather rapidly (Pizzo et al., 1988; 
Mast et al., 1991), and the stability time of vaspin-KLK14 complexes should therefore allow 
potential in vivo relevance. Together, these results demonstrate that vaspin is a multi-specific 
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serpin which utilizes individual exosites for the inhibition of its target proteases despite its 
unfavored RCL residue on the prime site of the scissile bond. Yet, specific exosite(s) 
important for KLK14 recognition and inhibition remain unknown.   
Alike other common serpins such as antithrombin (Serpin C1), heparin-cofactor II (Serpin 
D1) or protein C inhibitor (Serpin A5), vaspin is a heparin-binding serpin and heparin 
accelerates KLK7 inhibition by vaspin via the template-bridging mechanism (Ulbricht et al., 
2017). To evaluate the effect of heparin on KLK14 inhibition, vaspin and KLK14 were 
incubated in the presence of increasing concentrations of heparin. In contrast to the inhibition 
of KLK7, the complex formation of KLK14 and vaspin wt was inhibited by heparin for all 
concentrations investigated (Figure 2A), yet RCL cleavage still occurred. KLK14-cleaved 
vaspin in the presence of heparin migrated slightly lower that without heparin which may 
indicate additional and specific processing in the presence of heparin.  
Altered migration of vaspin molecules (full length or cleaved) in the presence of heparin was 
not observed before (Ulbricht et al., 2017). We used mass spectrometry to analyzed the 
appearance of additional vaspin peptides after cleavage by KLK14 in the presence of 
increasing heparin concentrations. While acquisition of peptide and protein spectra was not 
feasible for higher concentrations of heparin (>1x mol/mol to vaspin), we did detect 
additional peptide fragments after incubation of vaspin with KLK14 in the presence of 
equimolar heparin (data not shown). These peptides were in the range of 5 kDa which is in 
line with the band shift observed in the SDS-PAGE gels. Yet, we could not detect the 
corresponding full protein peaks, and due to the size we could not sequence the peptides by 
MSMS. We conclude that in the presence of heparin there is additional vaspin cleavage by 
KLK14, but the exact cleavage site remains unclear. 
Thus, for vaspin-KLK14 complex formation, heparin binding may block or interfere with 
crucial, yet unknown exosite interactions. Similar findings have been reported for the reaction 
of kallistatin (Serpin A4) and tissue kallikrein (KLK1), with heparin preventing protease 
inhibition by the serpin (Chen et al., 2000). For kallistatin, a positively charged loop functions 
as both the heparin binding site (Chen et al., 2001) and as exosite contact for KLK1 (Chen 
et al., 2000). Yet, while the location of these basic residues in kallistatin is corresponding to 
R301 and R302 of vaspin, our data demonstrated that this position, while essential for KLK7 
inhibition, is not contributing to heparin binding (Ulbricht et al., 2017), nor is it important for 
KLK14 inhibition by vaspin. Furthermore, as KLK7 is also inhibited by kallistatin (Luo and 
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Jiang, 2006), it would be interesting to see how heparin affects the inhibition of KLK7 by 
kallistatin. The presence of heparin may have similarly opposing effects as observed for 
vaspin inhibition of KLK7 and KLK14, respectively. 
Finally, glycosylation of vaspin has been reported at three different sites (N221, N233 and 
N267), two of them in close proximity of the RCL (Oertwig et al., 2017). As already 
demonstrated for KLK7, glycosylation of vaspin also slowed down inhibition of KLK14 
compared to unglycosylated vaspin (Figure 2B) but did not prevent complex formation.  
Recent evidences indicate anti-inflammatory actions as a major function of vaspin. These 
protective functions of vaspin in diverse tissues are exerted via both, regulation of protease 
activity and interaction with cell surface molecules. Overexpression of vaspin in adipose 
tissue protects mice from obesity-induced adipose tissue inflammation and insulin resistance 
and vice versa, with the knock-out of the vaspin gene metabolic functions deteriorate under 
high fat diet (Nakatsuka et al., 2012). Interestingly, inactive vaspin mutant A369P failed to 
improve glucose tolerance in high fat diet-induced insulin resistant mice (Heiker et al., 2013), 
suggesting the regulation of protease activity to contribute to these effects. Following the 
identification of KLK7 as a protease target of vaspin, we have recently shown, that knock out 
of the Klk7 gene in adipose tissue reduced obesity-induced local and systemic inflammation 
and improved insulin sensitivity in mice (Zieger et al., 2017).   
Thus, the identification of target proteases, such as KLK7 and also KLK14 will contribute to 
deeper mechanistic understanding of the protective effects of vaspin in obesity and metabolic 
diseases. Furthermore, they also may lead to new findings on KLK functions in tissues that 
have not been in the focus of KLK research yet. For instance, KLK14 is expressed in 
significant amounts in pancreas and adipose tissue according to the human protein atlas 
(Uhlén et al., 2015) and it is tempting to speculate on potential functional relevance of 
KLK14 in obesity and/or diabetes similar to KLK7. Finally, efforts to identify the 
physiological substrates of KLK7 and KLK14 are key to the detailed understanding of 
molecular pathways regulated by these proteases. This may lead to new pharmacologic 
strategies to treat obesity associated diseases. 
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Tables and figures 
Table 1 Kinetic parameters for KLK inhibition by vaspin wt and variants. 
KLK7 KLK14 
Vaspin variant / Protease 
ka SI ka SI 
wt 12.3 ± 0.3a 3.6 ± 0.3a 1.0 ± 0.1 3.6 ± 0.3c 
R302A 0.3 ± 0.1a 2.7 ± 0.6a 1.5 ± 0.2 3.1c 
D305A 89.7 ± 14.7 1.8 ± 0.4 1.2b 3.0c 
aData from Ulbricht et al. (2015); ka (mM-1 s-1); SI (I / E (mol / mol)); I Inhibitor; E Enzyme; data 
presented as means of at least three experiments ± S.D.; bdetermined once; cdensitometric estimation. 
A continuous method was applied for vaspin variant D305A using 10 nM KLK7, 25 µM fluorogenic 
peptide (Mca-Arg-Pro-Lys-Pro-Val-Glu~Nva-Trp-Arg-Lys(Dnp)-NH2 trifluoroacetate salt) and 
various vaspin concentrations (vaspin: KLK7 ratio 2.5-25:1). SI determination was performed using 
19.2 nM KLK7, 10 µM NFF3 and various vaspin concentrations (vaspin: KLK7 ratio 0.25-3:1). For 
KLK14, a discontinuous method was applied using 4 nM KLK14, 100 µM fluorogenic peptide (Boc-
Val-Pro-Arg-AMC) and 100-fold excess of vaspin. Measurements were made after 20 min of 
incubation time. Residual KLK7 activity was measured on a FlexStation3 Multi-Mode Microplate 
Reader (Molecular Devices). Second-order rate constants for both proteases were determined as 
described previously (Ulbricht et al., 2015). SI were estimated using the band intensity of complexed 
and cleaved vaspin divided by the band intensity of complexed vaspin as described previously 
(Ulbricht et al., 2015). 
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Figure 1 Complex formation analyses of vaspin wt and variants with KLK7 and 
KLK14.  
SDS-analysis of inhibition complex formation reveals vaspin as a multi-specific serpin which 
utilizes individual exosites for the inhibition of its target proteases. Vaspin wt or mutants 
(R302A (RA) and D305A (DA), respectively) were incubated with (A) KLK7 or (B) KLK14 
for indicated times. (C) SDS-PAGE analysis of the vaspin-KLK14 reaction using a vaspin 
substrate variant. Vaspin substrate variant R211A/K359A/A369P (P10 Pro) was incubated 
with KLK14 for three and 24 h. (D) Analysis of complex formation of vaspin RCL-mutant 
E379S (ES, P1’ residue) with KLK14 in comparison to the reaction with the wt vaspin and 
with the inhibition of KLK7 (note the much shorter reaction time for KLK7). (E) Vaspin 
variants were incubated with KLK14 for 24 h. Human vaspin wt and variants were expressed 
in and purified from E.coli as described previously (Ulbricht et al., 2015). KLK7 and KLK14 
(both from R&D) were activated with thermolysin (R&D) according to manufacturer’s 
protocol. 0.5 µM protease was incubated with vaspin wt or variant (protease: serpin molar 
ratio of 2:1) in TBS (20 mM Tris, 150 mM NaCl, pH 7.5) for indicated times. Reactions were 
stopped by adding reducing SDS sample buffer and immediately heated at 95°C for 5 min. 
SDS-PAGE was performed as previously described (Ulbricht et al., 2015) and gels were 
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silver stained for protein detection. Indicated bands are: 1 – vaspin-protease complex;  
2 – full-length vaspin; 3 – N-terminally cleaved vaspin; 4 – RCL-cleaved vaspin; 5 – vaspin 
fragment; 6 – protease; 7– thermolysin; con – vaspin only. 
 
Figure 2 Complex formation analyses of vaspin wt with KLK14 and heparin.  
SDS-analysis of vaspin: KLK14 complex formation with (A) heparin and (B) in HEK-cells. 
Human vaspin wt expression, purification and activation was performed as described in 
Figure 1. (A) 0.5 µM protease was incubated with vaspin wt (protease: serpin molar ratio 2:1) 
in TBS (20 mM Tris, 150 mM NaCl, pH 7.5) for 180 minutes and indicated vaspin: heparin 
ratios (unfractionated heparin from Sigma Aldrich). In contrast to KLK7, complex formation 
of KLK14 and vaspin wt was inhibited by heparin for all concentrations investigated. (B) 
366 nM vaspin wt expressed in HEK-cells (BioLegend) was incubated with KLK14 (serpin: 
protease ratio of 1:1) for indicated times. Glycosylation of vaspin did not prevent complex 
formation. Samples were analyzed as described in Figure 1. Indicated bands are: 1 –  
vaspin-KLK14 complex; 2 – full-length vaspin; 3 – N-terminally cleaved vaspin; 4 –  
RCL-cleaved vaspin; 5 – vaspin fragment; 6 – KLK14; con – vaspin only. 
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Supplementary table and figures 
Supplementary Table 1 Recombinant vaspin-derived peptides identified by MS analysis 
(as in Supplementary Figure 1). 
m/z 
expected 
m/z 
observed Mono AA Sequence 
2270.022 2269.993 -0.029 1-19 GHHHHHHHHHHSSGHIEGR 
3337.556 3337.417 -0.139 1-28 GHHHHHHHHHHSSGHIEGRHMKPSFSPR 
4037.407 4037.512 0.105 379-414 ETPLVVKIDKPYLLLIYSEKIPSVLFLGKIVNPIGK 
Sequence analysis after MALDI-TOF-MS was performed using Sequence Editor (Bruker Daltonics software). 
 
Supplementary Figure 1 MALDI-TOF MS analysis of vaspin peptides generated by 
KLK14 cleavage. 
MALDI-TOF MS results showing the relative abundance (a.u.) of N-terminal and C-terminal 
vaspin wt peptides obtained from vaspin protein cleavage by KLK14. Vaspin protein was 
generated and KLK14 was activated as described in Figure 1. 5.8 µM vaspin wt was 
incubated with KLK14 at a molar ratio of 5:1 for 4h. For MS analysis, samples were desalted 
using C18 ZipTipTM Pipette Tips C18 (10 µl, Merck, Darmstadt, Germany) according to the 
manufacturer’s protocol. MS was performed using the matrix SDHB (super 2.5-
dihydroxybenzoic acid) on an Ultraflex III mass spectrometer (Bruker Daltonics, Billerica, 
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USA) in the reflector modus. Measurements were analyzed by FlexAnalysis 3.0 (Bruker 
Daltonics software). 
 
Supplementary Figure 2 HPLC analysis of RCL-derived peptide (365-388) after KLK14 
incubation. 
Synthetic RCL-derived vaspin peptide (AA 365-388) was incubated at a molar ratio of 700:1 
with KLK7 for 4 h and 24 h at room temperature. The RCL-derived peptide was synthesized 
as previously described [1]. KLK14 was activated as described in Figure 1. After incubation, 
samples were analyzed by RP-HPLC (ProZap Expedite MSC18 Alltech column 10 mm x 
2,1 mm, 1,5 µm) using a water/acetonitrile (ACN) gradient with 0.1% TFA from 10-50% in 
5 min. 
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